Drug

Resveratrol

In clinical development

Actively researchedLate-stage developmentRising momentum

Also known as (E)-resveratrol, (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol, 3,4',5-trihydroxystilbene, 3,5,4'-trihydroxystilbene.

RxNorm1000492 ChEMBLCHEMBL165UNIIQ369O8926L

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effectiveness of Resveratrol Addition in Improving Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial

Clinical trial2026-06-10Completed · ClinicalTrials.gov

Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer's Disease.

Research2025-05-23International journal of molecular sciences

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Clinical trial2025-01-28Results expected Q1 2027 · ClinicalTrials.gov

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease: The NICE Trial

Clinical trial2025-01-14Results posted · ClinicalTrials.gov

Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap.

Research2024-10-07International journal of biological sciences

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Clinical trial2024-07-31Primary completion · ClinicalTrials.gov

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Clinical trial2024-07-30Completed · ClinicalTrials.gov

Assessment of Resveratrol, Alpha Lipoic Acid and Superoxide Dismutase on Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients With Neuropathy: A Randomized Control Trial

Clinical trial2024-05-05Completed · ClinicalTrials.gov

A Randomised Placebo-controlled Crossover Trial of Micronised Resveratrol as a Treatment for Friedreich Ataxia

Clinical trial2024-03-28Completed · ClinicalTrials.gov

Resveratrol as a Promising Nutraceutical: Implications in Gut Microbiota Modulation, Inflammatory Disorders, and Colorectal Cancer.

Research2024-03-16International journal of molecular sciences

Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial

Clinical trial2024-02-07Completed · ClinicalTrials.gov

Resveratrol (RV): A pharmacological review and call for further research.

Research2021-10-02Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Resveratrol

Aliases & brands

(E)-resveratrol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol3,4',5-trihydroxystilbene3,5,4'-trihydroxystilbene

RxNorm CUI

1000492

ChEMBL ID

CHEMBL165

UNII

Q369O8926L

Clinical trials

48 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 48

Early Phase 14Phase 16Phase 1 / 24Phase 218Phase 33Phase 42Phase N / A11

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial

Unknown statusPH IVKey trialFirst Affiliated Hospital Xi'an Jiaotong Universityn=2,7002018

The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial

CompletedPH IVHospital de Clinicas de Porto Alegren=442015

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease: The NICE Trial

CompletedPH IIINorthwestern Universityn=902023

Evolution of Pain at Three Months by Oral Resveratrol in Primary Knee Osteoarthritis: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial

CompletedPH IIIAssistance Publique - Hôpitaux de Parisn=1422022

Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome

CompletedPH IIIIVI Madridn=702019

Recent completions

Trials that read out recently, adding to the completed evidence base.

Effectiveness of Resveratrol Addition in Improving Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial

CompletedN/AUniversitas Sriwijayan=482026

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

CompletedPH IVirginia Commonwealth Universityn=82024

Assessment of Resveratrol, Alpha Lipoic Acid and Superoxide Dismutase on Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients With Neuropathy: A Randomized Control Trial

CompletedPH IIKhyber Medical University Peshawarn=1002024

A Randomised Placebo-controlled Crossover Trial of Micronised Resveratrol as a Treatment for Friedreich Ataxia

CompletedPH IIMurdoch Childrens Research Instituten=252024

Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial

CompletedN/AKhyber Medical University Peshawarn=1202024

Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease: a Mechanistic Approach

CompletedPH IVirginia Commonwealth Universityn=262023

Research activity

29 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20002025

Most influential

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.

Cell · 2006 · 3,088 cites

Resveratrol improves health and survival of mice on a high-calorie diet.

Nature · 2006 · 3,062 cites

High absorption but very low bioavailability of oral resveratrol in humans.

Drug metabolism and disposition: the biological fate of chemicals · 2004 · 1,312 cites

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Journal of neuroinflammation · 2017 · 472 cites

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

The British journal of nutrition · 2011 · 454 cites

Resveratrol and health--a comprehensive review of human clinical trials.

Molecular nutrition & food research · 2011 · 360 cites

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Alzheimer's Disease2

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Quercetin

Studied across 4 of the same disease areas as Resveratrol in the shared literature.

4 shared diseases1 shared paper

Pterostilbene

Studied across the same disease area as Resveratrol in the shared literature.

1 shared disease1 shared paper

Catechin

Frequently co-studied with Resveratrol in the research literature.

1 shared paper

Epigallocatechin gallate

Frequently co-studied with Resveratrol in the research literature.

1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials